Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.
Ann H PartridgeSamuel M NimanMonica RuggeriFedro Alessandro PeccatoriHatem A AzimMarco ColleoniCristina SauraChikako ShimizuAnna B SætersdalJudith R KroepAudrey MailliezEllen WarnerVirginia F BorgesFrédéric AmantAndrea GombosAkemi KataokaChristine Rousset-JablonskiSimona BorstnarJunko TakeiJeong E LeeJanice M WalsheManuel Ruíz-BorregoHalle C F MooreChristobel SaundersVesna Bjelic-RadisicSnezana SusnjarFatima CardosoKaren L SmithTeresa FerreiroKarin RibiKathryn RuddyRoswitha KammlerSarra El-AbedGiuseppe VialeMartine PiccartLarissa A KordeAron GoldhirschRichard D GelberOlivia Paganinull nullnull nullPublished in: The New England journal of medicine (2023)
Among select women with previous hormone receptor-positive early breast cancer, temporary interruption of endocrine therapy to attempt pregnancy did not confer a greater short-term risk of breast cancer events, including distant recurrence, than that in the external control cohort. Further follow-up is critical to inform longer-term safety. (Funded by ETOP IBCSG Partners Foundation and others; POSITIVE ClinicalTrials.gov number, NCT02308085.).